Akeso’s new drug application for gumokimab, an IL-17-targeting antibody for plaque psoriasis, has been accepted in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback